Establishing and Extending the Use of Therapeutic Drug Monitoring in Neuropsychopharmacology

Georgios Schoretsanitis,(Guest Editor)

DOI: https://doi.org/10.1097/ftd.0000000000001171

2024-03-16

Therapeutic Drug Monitoring

Abstract:Compared with that in previous decades, a prolonged phase of marked stagnation in the development of novel neuropsychopharmacological agents has recently been observed. 1 Along with this lack of breakthroughs, there has been increasing awareness of the need to understand the effectiveness and tolerability patterns of well-established and widely prescribed psychotropic agents. In contrast to research regarding the identification of reliable treatment biomarkers, therapeutic drug monitoring (TDM) is neither novel nor impressively innovative. However, TDM remains among the few valuable routine clinical tools in neuropsychopharmacology that essentially account for interindividual variability. This special issue of Therapeutic Drug Monitoring focuses on the unfolding potential of TDM as part of the clinical routine for neuropsychotropic agents. Scherf-Clavel et al 2 guide us through the frequently unseen parts of the TDM process, including various steps from requesting TDM to obtaining and integrating TDM results into clinical decision algorithms. A critical aspect of TDM utility in clinical routine is the turnaround time, that is, the time between requesting TDM and communicating TDM results. Vincent et al 3 show how short turnaround times for clozapine have the potential to transform TDM into a first-line decision-making tool in sudden or unforeseen situations. These situations may be related to the abrupt drug bioavailability changes linked to immunologic reactions 4 or bariatric operations 5 and may ultimately lead to side effects. 6,7

pharmacology & pharmacy,medical laboratory technology,toxicology